Will Bortezomib Meet the WHO Need for Future Cancer Treatments?


BortezomibThe World Health Organization has predicted over 20 million new cancer cases in 2015 worldwide. This seemingly unbelievable number is not only astonishing; it is also a dire warning from the WHO. With the future onslaught of patients needing cancer care and treatments, the WHO has been urging researchers to continue to develop new products to meet the needs of these patients. Bortezomib, also known as Velcade, is a successful treatment for both myeloma and lymphoma, and has a patent expiration of May 3, 2017. As a sterile injectable medication, used to treat both multiple myeloma and mantle cell lymphoma, this effectual treatment is administered as either an injection into the vein or subcutaneously. The patent expiration of bortezomib, which is marketed by Millennium Pharmaceuticals, opens a pathway to greatly needed generic alternatives of this powerful medication.

According to the Oncology Market Leaders – Analyses and Outlook – 2010-2025 report, the aging of the population around the world, and medical therapies alongside lifestyle changes in developing nations has highlighted the need for continued viable cancer care.  The aforementioned report stressed the future necessity around the world for more oncologic research, medications, treatments and development. Patients with multiple myeloma or mantle cell lymphoma, particularly those patients who have received at least one prior treatment, are eligible for treatment with bortezomib. While this patient population may not appear to be numerous, the demand is impressive. Per IMS Health, US sales of Velcade for the 12 months ending October 31, 2012, were $740 million.

Patients with previously untreated myeloma are typically administered bortezomib in nine 6 week cycles. Each treatment cycle is 11 days of therapy, followed by a 10-day rest period, another 11 days of therapy, and a second 10-day rest cycle. Bortezomib is usually administered in combination with melphalan and prednisone. For patients with relapsed or refractory myeloma, bortezomib is typically given in eight three-week cycles.

LGM Pharma supplies the Bortezomib CAS# 179324-69-7 API for R&D purposes, as well as the Bortezomib TEVA API for compounding purposes in the U.S., and offers clients complete support throughout the R&D process.

 

Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.

  • Share: